Charles River Laboratories (CRL) Tops Q3 EPS by 17c, provides guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts CRL Hot Sheet
Price: $345.37 +1.68%
Revenue Growth %: -4.0%
Financial Fact:
Net sales related to products: 132.87M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Revenue Growth %: -4.0%
Financial Fact:
Net sales related to products: 132.87M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Charles River Laboratories (NYSE: CRL) reported Q3 EPS of $2.59, $0.17 better than the analyst estimate of $2.42. Revenue for the quarter came in at $1.01 billion versus the consensus estimate of $976 million.
GUIDANCE:
Charles River Laboratories sees FY2024 EPS of $10.10-$10.30, versus the consensus of $10.00.
For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- Graphano Energy amends private placement to add flow-through shares
- SLM (SLM) Misses Q3 EPS by 36c; lowers guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
